Thursday, July 26, 2012
Public Health Agency of Canada researchers have shown that a cocktail of three
antibodies, dubbed ZMab, improved the survival of nonhuman
primates infected by Ebola virus.1 ZMab is licensed to Defyrus Inc.,
which plans to establish commercial-scale manufacture of the therapy and carry
out biodistribution and toxicology studies.
Mouse vs. human mAb
Baas, T. SciBX 5(29); doi:10.1038/scibx.2012.748
Published online July 26, 2012
1. Qiu, X. et al. Sci.
Transl. Med.; published online June 13, 2012;
Contact: Gary P. Kobinger, University of Manitoba, Winnipeg, Manitoba,
X. et al. Clin. Immunol. 141, 218-227 (2011)
3. Qiu, X. et al. PLoS
Negl. Trop. Dis. 6, e1575; published online March 20, 2012;
AND INSTITUTIONS MENTIONED
Defyrus Inc., Toronto, Ontario, Canada
Public Health Agency of Canada, Winnipeg, Manitoba, Canada
Sarepta Therapeutics Inc. (NASDAQ:SRPT), Bothell, Wash.
University of Manitoba, Winnipeg, Manitoba, Canada